Results 91 to 100 of about 766 (122)
Some of the next articles are maybe not open access.
[Carbocysteine in the treatment of recurrent bronchitis in infants].
Ceskoslovenska pediatrie, 1992In a group of 51 children aged 6-24 months the therapeutic effectiveness of the mucolytic preparation carbocysteine was tested and compared with the effect of Ipeca syrup. The effect was evaluated by means of a point score comprising changes of the clinical picture of the disease and the use of other laboratory examinations.
P, Bánovcin +4 more
openaire +1 more source
Biochemical Pharmacology, 1991
Abstract The metabolism of the mucolytic agent carbocysteine ( S- carboxymethyl- l -cysteine , CMC) has attracted substantial interest during recent years [1]. It has been reported that sulphoxidation of CMC and its cysteinyl metabolites consitutes a major pathway of biotransformation.
C O, Meese +4 more
openaire +2 more sources
Abstract The metabolism of the mucolytic agent carbocysteine ( S- carboxymethyl- l -cysteine , CMC) has attracted substantial interest during recent years [1]. It has been reported that sulphoxidation of CMC and its cysteinyl metabolites consitutes a major pathway of biotransformation.
C O, Meese +4 more
openaire +2 more sources
Evaluation of the activity of the carbocysteine-sobrerol combination on mucus spinnability.
International journal of clinical pharmacology research, 1988Among the rheological properties of bronchial mucus, "spinnability", i.e. the ability to form threads under the effect of traction, should be regarded as the most closely related to the mucociliary transport function. In the present study the "spinnability" parameter was included in the functional tests aimed at evaluating the efficacy of the ...
DISTEFANO SM +5 more
openaire +2 more sources
Drug intelligence & clinical pharmacy, 1988
Carbocysteine is prescribed for conditions characterized by the accumulation of excessive mucus. Although often described as a mucolytic, its function is probably that of mucoregulation, which results in physical changes in accumulated secretions that are favorable in terms of clearance.
openaire +1 more source
Carbocysteine is prescribed for conditions characterized by the accumulation of excessive mucus. Although often described as a mucolytic, its function is probably that of mucoregulation, which results in physical changes in accumulated secretions that are favorable in terms of clearance.
openaire +1 more source
Efficacy of erdosteine, carbocysteine, and N-acetylcysteine in COPD: a comparative analysis
General practice and primary care, 2019Background: Although mucolytics are useful for the management of COPD, there is paucity of data comparing the efficacy of the different mucolytic agents in reducing the risk acute exacerbation of COPD (AECOPD). Aims and Objectives: To compare the pooled data from trials of mucolytics to evaluate their efficacy profile in COPD.
Mario Cazzola +4 more
openaire +1 more source
Efficacy of carbocystein as add-on therapy for adults with light to moderate occupational COPD
European Respiratory Journal, 2014Background The main symptoms of COPD are dyspnoe, cough and phlegm production. GOLD 2014 recommends to include carbocystein as a mucoregulative drug in treatment patients with severe COPD. Carbocystein (CS)is a mucolytic drug, which reduces the viscosity of sputum. Undoubtedly it can be useful for elimination of
Olyga Vasilyeva +2 more
openaire +1 more source
Bioavailability of two formulations of carbocysteine in healthy volunteers
European Journal of Pharmacology, 1990A. Sabo, V. Jakovljevi, B. Bani
openaire +1 more source
CARBOCYSTEINE THERAPY IN OLDER PEOPLE WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Journal of the American Geriatrics Society, 2006Mitchell, SC, Steventon, GB
openaire +3 more sources